Skip to main content

Table 2 Associations between breast tumor markers and other tumor characteristics at diagnosis, Nurses’ Health Study II

From: Erythrocyte membrane fatty acids and breast cancer risk by tumor tissue expression of immuno-inflammatory markers and fatty acid synthase: a nested case-control study

Other tumor characteristics n1 Breast tumor markers
percent positivity, median (IQR)2
   CD4 CD8 CD20 CD163 COX-2 FAS
ER status
 ER+ 162 3.4 (1.5–9.6) 5.5 (2.4–10.9) 0.5 (0.1–1.7) 13.4 (9.9–16.7) 26.3 (13.6–43.9) 86.3 (74.1–90.6)
 ER− 41 3.5 (1.2–11.7) 8.2 (1.7–16.3) 0.3 (0.0–3.1) 12.9 (10.8–17.6) 25.2 (12.5–38.3) 73.1 (39.3–88.3)
P value3   0.78 0.36 0.79 0.75 0.66 0.001
PR status
 PR+ 144 3.4 (1.5–9.0) 5.5 (2.3–10.9) 0.4 (0.1–1.7) 13.3 (9.9–16.7) 26.5 (13.9–43.9) 87.6 (76.1–91.1)
 PR− 58 3.5 (1.5–12.4) 5.9 (2.0–15.4) 0.4 (0.1–2.9) 13.3 (10.9–18.4) 24.3 (12.3–43.3) 72.3 (41.0–85.5)
P value3   0.35 0.50 0.81 0.29 0.51 < 0.001
HER2 status
 HER2+ 27 5.0 (2.1–7.9) 6.2 (2.6–13.2) 0.6 (0.1–1.8) 13.5 (9.0–17.5) 16.0 (10.6–28.0) 85.4 (73.2–92.4)
 HER2− 104 3.0 (1.5–10.1) 7.0 (2.3–13.1) 0.4 (0.1–1.8) 13.3 (10.2–16.6) 29.9 (17.9–43.9) 84.1 (68.0–89.3)
P value3   0.55 0.94 0.88 0.94 0.05 0.44
Tumor grade
 Grade I 41 3.3 (1.1–6.7) 4.8 (1.9–8.7) 0.6 (0.1–3.1) 12.5 (9.4–16.1) 28.2 (12.6–50.9) 88.6 (80.4–94.8)
 Grade II 71 2.4 (1.3–9.1) 5.7 (2.0–13.1) 0.4 (0.1–1.7) 13.3 (9.9–16.7) 25.4 (13.4–42.9) 84.6 (68.7–90.2)
 Grade III 58 3.0 (1.5–8.3) 7.6 (2.7–15.4) 0.2 (0.0–1.2) 13.4 (10.8–16.5) 29.9 (15.2–43.3) 80.1 (63.6–88.2)
P value3   0.90 0.19 0.14 0.50 0.80 0.003
Tumor size
 < 2 cm 126 3.6 (1.5–9.0) 6.6 (2.2–12.3) 0.4 (0.1–1.7) 13.3 (10.2–16.7) 29.2 (14.8–45.0) 84.5 (70.6–89.3)
 ≥ 2 cm 50 2.1 (1.0–5.5) 5.5 (1.7–10.9) 0.2 (0.1–1.0) 12.8 (10.4–16.5) 24.1 (12.0–43.3) 83.6 (69.3–91.1)
P value3   0.06 0.58 0.30 0.67 0.25 0.76
Nodal involvement
 No 141 4.4 (1.6–9.9) 6.8 (2.3–13.1) 0.7 (0.1–2.1) 13.3 (10.3–16.7) 30.0 (15.0–45.5) 85.4 (70.8–89.9)
 Yes 58 2.1 (1.0–7.2) 5.5 (2.2–10.8) 0.2 (0.1–2.0) 13.0 (10.1–16.7) 22.1 (12.0–38.6) 83.0 (64.7–90.0)
P value3   0.02 0.54 0.19 0.84 0.06 0.46
  1. Abbreviations: IQR interquartile range, COX-2 cyclooxygenase-2, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2
  2. 1Total n varies across markers depending on the number of cases with data for each marker
  3. 2Measured in stroma (CD4, CD8, CD20, CD163) or epithelium (COX-2, FAS). COX-2 was defined as the percentage of epithelial area staining positive for at least one of the two antibodies (Cayman Chemical or Thermo Fisher Scientific)
  4. 3P value calculated using a Wilcoxon rank-sum test (tumor characteristics with two categories) or a Kruskal-Wallis test (tumor characteristics with three categories)